98%
921
2 minutes
20
Objective: The aim of the present study was to provide practical considerations for assessing MD adherence during pregnancy based on the association with cardiometabolic risk.
Study Design: Longitudinal study.
Main Outcome Measures: A food frequency questionnaire was fulfilled by 152 pregnant women at the 16th gestational week (g.w.). We calculated the Mediterranean Food Pattern (MFP), the MD Scale (MDScale), the Short MD questionnaire (SMDQ), the MD Score (MedDietScore), and the MD scale for pregnant women (MDS-P). The cardiometabolic risk score consisted of pre-pregnancy body mass index, blood pressure, glucose, triglycerides, and high-density lipoprotein-cholesterol (at 16th and 34th g.w.).
Results: Multiple linear regression models showed that the MFP, the MedDietScore, and the SMDQ were associated with lower cardiometabolic risk at the 16th and 34th g.w. (β's: -0.193 to -0.415, all p < 0.05); and the MDS-P at the 34th g.w. (β = -0.349, p < 0.01). A comparison of these models with the J test showed that the MFP and the MedDietScore outperformed the SMDQ at the 16th g.w. (p's < 0.05); while the MedDietScore outperformed the SMDQ, MFP, and MDS-P (p's < 0.05) at the 34th g.w. Receiver-Operating-Characteristic-derived thresholds for the MFP, MedDietScore and MDS-P indices were 21, 30, and 6 points, respectively, to identify women with high cardiometabolic risk.
Conclusion: The MFP and MedDietScore are recommended to assess MD adherence during pregnancy, as these showed the strongest associations with cardiometabolic risk. Our validated thresholds might assist in the detection of poor dietary patterns during pregnancy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.preghy.2022.11.007 | DOI Listing |
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Sleep
September 2025
Center for Sleep Medicine, Hospices Civils de Lyon, Lyon 1 University, Lyon, F-69000, France.
Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program.
View Article and Find Full Text PDFChronobiol Int
September 2025
Consultant, Wayzek Science, St Paul, Minnesota, USA.
Understanding how sleep affects the risk of incident chronic conditions in midlife may reinforce the importance of a healthy sleep pattern for healthy aging and cardiometabolic health. The objective of the study was to examine associations of sleep duration and quality with incident obesity, diabetes and metabolic syndrome in mid-aged adults. Participants without obesity ( = 381), diabetes ( = 509), or metabolic syndrome ( = 487) from the Biomarker Projects in Midlife in the United States study were examined separately for baseline sleep duration and quality and their associations with incident obesity, diabetes, or metabolic syndrome after an average follow-up of 12 years.
View Article and Find Full Text PDFJ Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory approval. However, employing composite endpoints introduces complexities into health technology assessments (HTAs), particularly in economic modeling, due to the varying clinical significance and cost implications of the components. In this paper, we explore best modeling practice for HTAs that are based on clinical trials that employ composite endpoints.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
September 2025
School of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.